View on market: Volatility Prevails, Market is searching for better value
Australian dollar and U.S. equity futures rose in early Asian trading on Monday amid signs of improving ties between the U.S. and China, while contracts for benchmarks in Asia showed muted moves. Futures contracts for Australian and Hong Kong equities were slightly lower, mirroring the decline in U.S. stocks on Friday, while Japanese contracts made a small advance. The small advance on Monday follows positive signs that Sino-U.S. relations will thaw, and also ongoing optimism that China will unleash fresh stimulus to boost its flagging recovery. U.S. stock and bond markets will be closed for the Juneteenth holiday Monday. The S&P 500 declined 0.4% on Friday to end a six-session streak of advances as investors look for more insight on Federal Reserve interest rate decisions. Meanwhile, Brent crude was trading around $76 a barrel and West Texas Intermediate was around $71. The yield on the 10-year U.S. bond was trading at 3.76%, whereas Bitcoin was below 27,000-level. At 5:40 a.m., the Singapore-traded SGX Nifty, an early indicator of the Nifty 50 Index’s performance in India was up 0.01% at 18900.5.
Economic Calendar:
- USD : Building Permits (May) on 20th June, 2023
- USD : Initial Jobless Claims on 22nd June, 2023
- INR : FX Reserves, USD on 23rd June, 2023
- INR : Foreign Debt (USD) (Q1) on 30th June, 2023
Brokerage Radar:
CITI ON GATEWAY DISTRIPARKS: Buy, TP Rs 90; Continue To Maintain Its Market Share In Key Markets; Faridabad Terminal Will Also Start Double Stacking In 4-5 Months; Focus Will Remain On The Western DFC; Valuation Looks Attractive
JEFFERIES ON NYKAA: Buy Call; Target Rs 200; Mgmt Sounded Positive On Its Industry Outlook; Premiumisation Trend Plays Well In Favour Of Co; Outlook On Profitability Is Also Positive
JEFFERIES ON ASHOK LEYLAND: Buy, TP raised to Rs 195; M&HCF Medium-term Target At 35%, 25% In 2-3.5t LCVs; Medium-term EBITDA Margin Target Is Mid-teen; Other Focus Areas Include Expanding Export & Defence Footprint; Building EV & Alternate Powertrains Will Also Be Focus Areas
International Markets
U.S & Europe:
Particulars | 16th June | Chg. | Chg.(%) |
Nasdaq | 13689.57 | -93.25 | -0.68 |
Dow | 34299.12 | -108.94 | -0.32 |
FTSE | 7642.72 | 14.46 | 0.19 |
CAC | 7388.65 | 97.74 | 1.32 |
DAX | 16357.63 | 67.51 | 0.41 |
Dow Fut.* | 34262.00 | -37.10 | -0.11 |
Asian markets
Particulars | 19th June | Chg. | Chg.(%) |
SGX Nifty | 18919.50 | 21.50 | 0.11 |
Nikkei | 33724.60 | 18.52 | 0.05 |
Straits Times | 3242.41 | -17.62 | -0.54 |
Hang Seng | 19855.18 | -185.19 | -0.92 |
Shanghai | 3258.29 | -15.04 | -0.46 |
ADR Watch:
Particulars | 16th June | Chg. | Chg.(%) |
Dr. Reddy | 60.27 | 0.86 | 1.45 |
HDFC Bank | 66.45 | 1.85 | 2.86 |
ICICI Bank | 22.87 | 0.00 | 0.00 |
Infosys | 15.83 | 0.21 | 1.34 |
Wipro | 4.67 | -0.03 | -0.64 |
Commodities & Currency
Particulars | Current Price | Chg.(%) |
USD/INR | 81.97 | 0.07 |
Brent | 75.42 | -1.55 |
Gold | 1967.75 | -0.18 |
Silver | 24.170 | 0.18 |
FIIs & DIIs:
Particulars | 16th June | 15th June |
FIIs | 794.78 | 3085.51 |
DIIs | 681.33 | -297.88 |
News Update:
Adani Enterprises: Company’s unit, Adani Digital Labs, has signed a share purchase agreement to acquire a 100% stake in Stark Enterprises. Stark Enterprises, also known as Trainman, is an online train booking and information platform.
Axis Bank: Axis Bank appointed former RBI Deputy Governor N.S. Vishwanathan as Non-Executive Part-Time Chairman with effect from Oct. 27, 2023.
Castrol India: Castrol and Mahindra Insurance Brokers have signed an agreement to distribute insurance policies. The deal will allow Castrol Auto Service workshops to distribute eligible insurance policies, and these workshops will be able to register as cashless claim sites with insurance companies.
Trident: The company’s unit, Trident Home Textiles, incorporated a wholly-owned subsidiary, Trident Global B.V., in the Netherlands. Trident Global will carry out the wholesale business of textiles, paper, non-food consumer goods, and clothing accessories.
Axiscades Technologies: The company agreed to acquire a 100% stake in Add Solution GmbH for 5.5 million euros (Rs 49.27 crore).
Dr Reddy’s Laboratories: The US Food and Drug Administration (USFDA) completed a good manufacturing practice (GMP) inspection at company’s API manufacturing facility in Bollaram, Hyderabad. The inspection was conducted during June 12 and June 16, and closed with zero observations. After inspection by the USFDA of the formulations facility in Srikakulam in May 2023, the company had received the Establishment Inspection Report (EIR). The USFDA has classified the said inspection as Voluntary Action Indicated (VAI).
HDFC Bank: Pursuant to the request by HDFC Bank, the Reserve Bank of India (RBI) has advised the lender that it may hold the commercial papers that were issued till date by HDFC, till their maturity. The bank should not roll over or reissue any commercial paper after the effective date of the proposed amalgamation. The bank will also approach the RBI with the crystalized amounts of all the liabilities of HDFC as of the effective date.
Source: Moneycontrol, Bloomberg Quint, Investing
Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014
Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Kiran Tahlani, Elite Wealth Limited, kirantahlani@elitestock.com
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or e-mailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
- Reports
- a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
- Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL
Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or brokerage services transactions of the subject company.
(4) EWL or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL has never been engaged in market making activity for the subject company;
(6) EWL shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.